Evidence map›Paper›PMID 39030424›Full record

ArticlePsychopharmacology2025

Correction to: Unraveling psilocybin's therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression.

Magdalena Kolasa, Agnieszka Nikiforuk, Agata Korlatowicz, Joanna Solich, Agnieszka Potasiewicz, Marta Dziedzicka-Wasylewska, Ryszard Bugno, Adam Hogendorf, Andrzej Bojarski, Agata Faron-Górecka

Abstract readPublished Erratum
In one paragraph

Article in Psychopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Magdalena KolasaDepartment of Pharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
Agnieszka NikiforukDepartment of Behavioral Neuroscience & Drug Development, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
Agata KorlatowiczDepartment of Pharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
Joanna SolichDepartment of Pharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
Agnieszka PotasiewiczDepartment of Behavioral Neuroscience & Drug Development, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
Marta Dziedzicka-WasylewskaDepartment of Pharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
Ryszard BugnoDepartment of Medicinal Chemistry, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
Adam HogendorfDepartment of Medicinal Chemistry, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
Andrzej BojarskiDepartment of Medicinal Chemistry, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland.
Agata Faron-GóreckaDepartment of Pharmacology, Maj Institute of Pharmacology Polish Academy of Sciences, Kraków, Poland. gorecka@if-pan.krakow.pl.ORCID https://orcid.org/0000-0002-8202-190X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39030424
PMCPMC12084163

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.